# Healthcare Reform
Latest news and articles about Healthcare Reform
Total: 5 articles found
The Price of a Breath: Why a Low-Cost Chinese Ventilator for ALS Struggled to Gain Traction
Despite a collaboration between activist Cai Lei and Haier producing a ventilator 80% cheaper than imports, the project faces low uptake due to trust issues and market skepticism. The case highlights the systemic difficulties in establishing a domestic medical device ecosystem for rare diseases in China.
China’s Biotech Ambitions: Shanghai Launches Elite Training to Bridge the Clinical Trial Talent Gap
Shanghai has launched a high-level training initiative to equip clinical trial Principal Investigators with the international leadership skills necessary to lead global research. The project aims to harmonize Chinese clinical standards with international benchmarks, supporting the global expansion of China's innovative drug industry.
A Bitter Pill for China’s Drugstores: National Price Cuts Reach the Medicine Cabinet
China's latest centralized drug procurement has included high-volume OTC Traditional Chinese Medicines for the first time, threatening the profitability of major pharmacy chains. This move forces a shift from high-margin retail sales toward a service-oriented business model as the government aggressively drives down household medical costs.
Prescription for Control: Beijing Tightens Oversight as Retail Pharmacy Giants Face Insurance Fraud Audits
Hunan authorities have launched a province-wide crackdown on major pharmacy chains, including Laobaixing Pharmacy, following an investigation into the misuse of medical insurance funds. The campaign introduces 'flying inspections' and mandatory corporate rectifications, reflecting a national push to eliminate fiscal leakages in the healthcare system.
Blood and Beauty: Boya Bio’s Aesthetics Misadventure Triggers 70% Profit Plunge
Boya Bio-Pharmaceutical saw its 2025 net profits crash by over 70% due to a massive impairment in its acquired medical aesthetics business and regulatory headwinds in the blood products market. The crisis is compounded by the sudden resignation of its CEO after only nine months, signaling deeper governance and strategic integration issues.